Palisade Bio, Inc. (NASDAQ: PALI) is a Healthcare company (Biotechnology) with a market capitalization of $181M. The Maz Rating grades it against the other companies in its sector.
Palisade Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.01, Palisade Bio, Inc. trades at 360.3x sales and 1.9x book value. Over the last twelve months it generated about $502488 of revenue and a net loss of $40M. It runs an operating margin of -9625.4% and a net margin of -8739.2%. It shows return on equity of -35.6%, return on invested capital of -42.7% and a free cash flow yield of -14.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 20.16. Over the past 52 weeks the share price ranged from $0.99 to $2.86, with a beta of 1.62.
Palisade Bio, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.